 Annovis Bio Inc NYSE: ANVS has completed a Type B meeting with the FDA regarding its planned Phase 3 studies of Buntanetap for the treatment of Parkinsons Disease PD as an offshoot of the Companys clinical program in Alzheimers Disease AD. Following the Companys submission of Phase 2 data and the chronic toxicology data in animals, the Company requested directions to further develop Buntanetap in PD. 